Emergent Biosolutions, Inc. (NYSE:EBS) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.32, Bloomberg Earnings reports. The business had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 EPS.

Emergent Biosolutions (NYSE EBS) traded up $2.97 during trading on Friday, reaching $43.03. The company had a trading volume of 1,630,000 shares, compared to its average volume of 243,066. The stock has a market cap of $1,773.35, a PE ratio of 22.77, a PEG ratio of 1.32 and a beta of 1.22. Emergent Biosolutions has a 1 year low of $24.70 and a 1 year high of $44.86. The company has a current ratio of 6.99, a quick ratio of 6.02 and a debt-to-equity ratio of 0.40.

Several research firms have recently issued reports on EBS. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Emergent Biosolutions currently has an average rating of “Buy” and an average price target of $45.00.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/emergent-biosolutions-inc-ebs-posts-quarterly-earnings-results-beats-estimates-by-0-32-eps/1679045.html.

In related news, Director Ronald Richard sold 22,415 shares of Emergent Biosolutions stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $40.00, for a total transaction of $896,600.00. Following the completion of the sale, the director now owns 24,676 shares in the company, valued at approximately $987,040. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $38.50, for a total value of $962,500.00. Following the sale, the chairman now owns 1,603,763 shares of the company’s stock, valued at approximately $61,744,875.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 180,227 shares of company stock valued at $6,993,970. 16.50% of the stock is currently owned by company insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.